New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy-Reference-Cited by-同舟云学术

New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy

Published:1995-06 Issue:6 Volume:31 Page:859-860
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Oliver R.T.D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference14 articles.

1. High serum prolactin associated with poor prognosis in carcinoma of the prostate;Mee;Br J Urol,1984

2. Clinical follow-up of prostatic cancer patients under intermittent treatment with fosfestrol and bromocriptine;Jeromin;Urol Int,1988

3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma;Crawford;N Engl J Med,1989

4. Effects of intermittent androgen suppression on androgen dependent tumours;Akakura;Cancer,1993

5. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer;Oliver;Cancer Surveys,1995

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture;ENDOCRINOLOGY;1999

2. Prolactin Is a Survival Factor for Androgen-Deprived Rat Dorsal and Lateral Prostate Epithelium in Organ Culture1;Endocrinology;1999-11-01

3. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer;Biotherapy;1996-03

4. Intermittent hormone therapy in prostate and breast cancers;European Journal of Cancer;1995-12

5. Does surgery disseminate or accelerate cancer?;The Lancet;1995-12